Regional Citrate Anticoagulation for RRT During V-V ECMO
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Anticoagulation is an essential component of all extracorporeal therapies. Currently
locoregional citrate anticoagulation is the recommended technique for continuous renal
replacement therapy (CRRT).
However, low clearance of citrate restricts its use to blood flow up to 150 mL/min,
preventing its use in ECMO.
Renal replacement therapy (RRT) is commonly provided to ECMO patients with AKI. In presence
of systemic heparinization for ECMO, additional anticoagulation for the CRRT circuit (i.e.
RCA) is usually not employed.
Nevertheless, thrombosis occurs more frequently in the CRRT circuit than the oxygenator
because of the slower blood flow.
The aim of this prospective, cross-over study is to assess, in patients undergoing CRRT
during veno-venous ECMO (vv-ECMO), the efficacy and safety of adding regional citrate
anticoagulation (RCA) for CRRT circuit anticoagulation.